UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033992
Receipt number R000038761
Scientific Title The effect of low dose tolvaptan after cardiovascular surgery
Date of disclosure of the study information 2018/09/03
Last modified on 2021/03/05 10:10:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The effect of low dose tolvaptan after cardiovascular surgery

Acronym

The effect of low dose tolvaptan after cardiovascular surgery

Scientific Title

The effect of low dose tolvaptan after cardiovascular surgery

Scientific Title:Acronym

The effect of low dose tolvaptan after cardiovascular surgery

Region

Japan


Condition

Condition

after cardiovascular surgery associated with cardiopulmonary bypass

Classification by specialty

Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

early return to preoperative weight by using tolvaptan after open heart surgery

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Whether returning to the target weight by the 6th postoperative day

Key secondary outcomes

worsening renal function, urine volume / body weight


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Azosemide 30 mg / day was administered from the 2nd postoperative day. Administer furosemide 10 to 40 mg as appropriate. Within 4 days to return to preoperative weight.

Interventions/Control_2

Azosemide 30 mg/day and tolvaptan 3.75 mg/day was administered from the 2nd postoperative day. Administer furosemide 10 to 40 mg as appropriate. Within 4 days to return to preoperative weight.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients after open heart surgery with cardiopulmonary bypass

Key exclusion criteria

Urgency or emergency operation
CKD (dialysis, eGFR<30)
Heart failure with EF<40%
Heart failure or infection within preoperative 4 weeks
Thoracoabdominal aortic replacement surgery and OPCAB
Artificial respiration management over 24 hours and reintroduction
Tolvaptan allergy
Without feeling dry mouth or water ingestion
Hypernatremia
Patients with pregnant, possibility of pregnancy and pregnancy wish
Using tolvaptan preoperatively

Target sample size

240


Research contact person

Name of lead principal investigator

1st name Tadaaki
Middle name
Last name Koyama

Organization

Kobe City Medical Center General Hospital

Division name

Cardiovascular Surgery

Zip code

650-0047

Address

2-1-1 Minatojimaminamimachi Chuouku Kobe City Hyogo Japan

TEL

078-302-4321

Email

koyamat@kcho.jp


Public contact

Name of contact person

1st name Tadaaki
Middle name
Last name Koyama

Organization

Kobe City Medical Center General Hospital

Division name

Cardiovascular Surgery

Zip code

650-0047

Address

2-1-1 Minatojimaminamimachi Chuouku Kobe City Hyogo Japan

TEL

078-302-4321

Homepage URL


Email

koyamat@kcho.jp


Sponsor or person

Institute

Kobe City Medical Center General Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe City Medical Center General Hospital

Address

2-1-1 Minatojimaminamimachi Chuouku Kobe City Hyogo Japan

Tel

078-302-4321

Email

rinken@kcho.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 09 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2018 Year 08 Month 24 Day

Date of IRB

2018 Year 08 Month 25 Day

Anticipated trial start date

2018 Year 09 Month 03 Day

Last follow-up date

2020 Year 12 Month 31 Day

Date of closure to data entry

2021 Year 01 Month 31 Day

Date trial data considered complete

2021 Year 02 Month 28 Day

Date analysis concluded

2021 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2018 Year 09 Month 02 Day

Last modified on

2021 Year 03 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038761


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name